Our results confirmed a significantly higher JAK2V617F VAF in homozygous carriers of JAK2 haplotypeGGCC_46/1 (C/C genotype) and a significant increase of the C/C genotype in ET pts with JAK2V617F VAF > 50%. Here, JAK2 is linked to essential thrombocythemia.